导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.56% | 1184/4773 |
| 近一周 | -0.08% | 1243/5467 |
| 近一月 | -5.07% | 2139/5421 |
| 近一季 | -12.46% | 3737/5238 |
| 近半年 | -2.65% | 2404/4931 |
| 近一年 | 8.51% | 1173/4400 |
| 近两年 | 89.77% | 717/2954 |
| 近三年 | 37.31% | 818/2253 |
| 成立以来 | 192.72% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.95% 625/4961 |
18.50% 1373/5312 |
- - |
- - |
| 2025 | 37.06% 915/4813 |
5.40% 783/3635 |
5.39% 600/4076 |
19.74% 2104/4524 |
3.04% 771/4813 |
| 2024 | -0.16% 2102/3463 |
-9.06% 2263/2808 |
-6.18% 1877/3014 |
12.70% 2299/3129 |
3.82% 761/3463 |
| 2023 | -6.77% 874/2656 |
11.55% 332/2280 |
-4.52% 1192/2385 |
-8.36% 1695/2515 |
-4.48% 1051/2655 |
| 2022 | -9.02% 163/2207 |
-9.50% 329/1919 |
5.77% 830/2016 |
-8.61% 213/2113 |
4.00% 608/2208 |
| 2021 | 29.82% 71/1822 |
-3.27% 791/1255 |
15.07% 238/1330 |
10.24% 126/1466 |
5.81% 264/1822 |
| 2020 | 32.94% 469/1250 |
-0.11% 179/1028 |
18.67% 328/1067 |
6.92% 813/1164 |
4.89% 825/1184 |
| 2019 | 40.15% 259/1092 |
31.68% 193/739 |
-6.95% 531/788 |
4.21% 211/850 |
9.76% 198/918 |
| 2018 | - - |
- - |
-0.22% 44/631 |
0.25% 156/660 |
-6.19% 43/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 万家中证1000指数增强C VS. 长安沪深300非周期A(740101) |